KNSA Surges 28% on EPS Revision, Record Revenue; AMC, BZUN, CLF Also Climb
Kiniksa Pharmaceuticals (KNSA) led with a 28.3% gain after its forward EPS growth estimate was revised to 39.7% and Q2 revenue hit a record $243.6M. AMC Entertainment jumped 25% on a 14.2pp EPS revision and record Q2 revenue of $1.6B. Cleveland-Cliffs (CLF) rose 23% after analysts lifted its EPS growth estimate to 246.8% and Q2 EBITDA tripled.
| Ticker | Sector | Detected | EPS Revision | Gain Since Detection |
|---|---|---|---|---|
| KNSA | Healthcare | 2026-07-23 | N/A | +28.3% |
| AMC | Communication Services | 2026-07-21 | +14.2pp | +25.0% |
| BZUN | Consumer Cyclical | 2026-07-24 | +2.2pp | +24.2% |
| CLF | Basic Materials | 2026-07-21 | +11.5pp | +23.0% |
| ATEC | Healthcare | 2026-07-23 | N/A | +17.5% |
Why did KNSA stock jump in July 2026?
KNSA jumped 28.3% (from $63.05 to $80.92) after its forward EPS growth estimate was revised to 39.7% on July 23, reinforced by record Q2 revenue of $243.6M and raised 2026 ARCALYST sales guidance to $980-$995M on July 28.
The company reported a 55% year-over-year revenue surge and advanced its KPL-387 pipeline into a pivotal Phase 3 trial. Our screener caught the EPS revision early, and the subsequent earnings beat confirmed the bullish trajectory.
KNSA EPS revision history → · Screener snapshot from 2026-07-23 →
FAQ: KNSA
Why did KNSA stock jump in July 2026?
KNSA jumped 28.3% after its forward EPS growth estimate was revised to 39.7% on July 23, followed by a stellar Q2 earnings report on July 28 with record revenue and raised guidance.
Is KNSA a buy after the rally?
KNSA's EPS growth estimate of 39.7% and strong commercial momentum for ARCALYST suggest continued upside, but the recent 28% move may have priced in near-term catalysts.
What is KNSA's EPS growth estimate?
KNSA's forward EPS growth estimate for the next year stands at 39.7% as of July 23, 2026.
Why did AMC stock jump in July 2026?
AMC jumped 25% (from $2.20 to $2.75) after analysts raised its forward EPS growth estimate from 42.0% to 56.2% on July 21, following record Q2 revenue of $1.6B and all-time high adjusted EBITDA of $321.4M reported on July 20.
The company benefited from blockbuster films like 'The Super Mario Galaxy Movie' and 'The Odyssey,' with domestic ticket revenue outpacing industry growth. Our screener detected the 14.2 percentage point EPS revision early, and the market confirmed the bullish thesis.
AMC EPS revision history → · Screener snapshot from 2026-07-21 →
FAQ: AMC
Why did AMC stock jump in July 2026?
AMC jumped 25% after its forward EPS growth estimate was revised from 42.0% to 56.2% on July 21, and the company reported record quarterly revenue of $1.6B on July 20.
What caused AMC's surge?
AMC's surge was driven by a 14.2 percentage point upward revision in EPS growth estimates and record Q2 results, including a 70% jump in adjusted EBITDA to $321.4M.
Is AMC a buy after the rally?
AMC's EPS revision to 56.2% growth and record cash flow are positive, but the stock remains volatile with a history of dilution; investors should weigh the improving fundamentals.
Why did BZUN stock jump in July 2026?
BZUN jumped 24.2% (from $2.48 to $3.08) after its forward EPS growth estimate was revised from 58.1% to 60.4% on July 24, with no additional company-specific news in the window.
The move aligns with a broader rotation into Chinese consumer cyclical stocks amid improving sentiment on e-commerce and retail recovery. Our screener flagged the 2.2 percentage point revision, and the price action suggests the market absorbed the higher growth expectations.
BZUN EPS revision history → · Screener snapshot from 2026-07-24 →
FAQ: BZUN
Why did BZUN stock jump recently?
BZUN jumped 24.2% after its forward EPS growth estimate was revised from 58.1% to 60.4% on July 24, driven by improving sector sentiment rather than company-specific news.
What is BZUN's EPS growth estimate?
BZUN's forward EPS growth estimate for the next year is 60.4% as of July 24, 2026.
What caused BZUN's surge?
BZUN's surge was triggered by an upward EPS revision and likely reflects broader momentum in Chinese consumer cyclicals and e-commerce stocks.
Why did CLF stock jump in July 2026?
CLF jumped 23% (from $9.25 to $11.38) after analysts raised its forward EPS growth estimate from 235.3% to 246.8% on July 21, reinforced by Q2 adjusted EBITDA tripling to $286M and a Q3 guidance of $575M reported on July 23.
The steelmaker benefited from higher automotive demand, Section 232 tariffs, and lower costs, with shipments expected to exceed 4.3 million tons in Q3. Our screener detected the 11.5 percentage point EPS revision early, and the earnings call confirmed the recovery narrative.
CLF EPS revision history → · Screener snapshot from 2026-07-21 →
FAQ: CLF
Why did CLF stock jump in July 2026?
CLF jumped 23% after its forward EPS growth estimate was revised from 235.3% to 246.8% on July 21, and Q2 earnings on July 23 showed EBITDA tripling to $286M with strong Q3 guidance.
Is CLF a buy after the rally?
CLF's EPS revision to 246.8% growth and Q3 EBITDA guidance of $575M suggest continued momentum, but the stock is sensitive to steel prices and trade policy.
What caused CLF's surge?
CLF's surge was driven by an 11.5 percentage point upward EPS revision and strong Q2 results, including a return to positive free cash flow and a tripling of EBITDA.
Why did ATEC stock jump in July 2026?
ATEC jumped 17.5% (from $8.21 to $9.65) after its forward EPS growth estimate was revised to 83.2% on July 23, with no immediate company-specific news in the window.
The healthcare sector saw a broader uptick in medical device stocks, and ATEC's strong growth narrative likely attracted investors seeking high EPS momentum. Our screener flagged the revision, and the price gain confirms the market's confidence in the company's earnings trajectory.
ATEC EPS revision history → · Screener snapshot from 2026-07-23 →
FAQ: ATEC
Why did ATEC stock jump recently?
ATEC jumped 17.5% after its forward EPS growth estimate was revised to 83.2% on July 23, with no additional news; the move reflects strong investor conviction in its earnings outlook.
What is ATEC's EPS growth estimate?
ATEC's forward EPS growth estimate for the next year is 83.2% as of July 23, 2026.
Is ATEC a buy after the rally?
ATEC's EPS growth estimate of 83.2% is among the highest in healthcare, but the lack of recent news means investors should monitor upcoming earnings for confirmation.
Today's top performers show that upward EPS revisions continue to drive significant price gains, especially when paired with strong earnings reports. The breadth across healthcare, communication services, consumer cyclical, and basic materials suggests a market that is rewarding improving fundamentals broadly.
How We Identify These Stocks
We track daily changes in forward EPS estimates across thousands of US equities. When a stock's next-year earnings growth estimate is revised upward — confirmed by improvement in current-year estimates — it enters our watchlist. The stocks above were flagged on their detection dates and have since delivered the strongest price returns among all detected stocks.
Explore today's full screener →